Resolution of Discordant Confirmatory Results on POC Reactive Rapid Tests: Florida’s Pilot Project HIV Diagnostics: New Developments and Challenges Feb.

Slides:

Advertisements

Similar presentations

HIV Counseling, Testing and Referral (CTR) Services at Boston Medical Center Vanessa J. Sasso, MSW Manager, HIV CTR Program Center for HIV/AIDS Care and.

Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section

HIV Counseling &Testing. Page 346 HIV and Risk Reduction (RR) Counseling Required at all scheduled visits Includes HIV Pre- and Post-test counseling.

Post Marketing Surveillance of Oraquick Rapid HIV Testing Laura Wesolowski, PhD Gale R Burstein, MD, MPH Julia Zhu, MS Steven Ethridge, MT Division of.

Unit 6 Diagnosis & Follow-up of HIV Infection

Evaluation of a Three Rapid Test Algorithm for the Diagnosis of HIV Infection at Point-of-Care Rapid Testing Facilities: Strategy 4 Data Needs. R. Boromisa.

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.

Comparative Performance of Dual 3rd Generation Immunoassays as a Potential Laboratory-Based HIV-1/2 Testing Strategy. B. Bennett, S. Fordan, O. David,

Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.

Evaluation of HIV Rapid Diagnostic Devices National STD Prevention Conference San Diego, CA 6 March 2002 Jennifer A. Malia, MS, MT WRAIR.

Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.

Addressing the Challenges Associated with Current HIV Diagnostic Algorithms Barbara G. Werner, PhD ID Consultant, MA State Laboratory 2007 HIV Diagnostics.

Integrating Rapid HIV Testing in Emergency Care Improves HIV Detection Evan M. Cadoff, MD Robert Wood Johnson Medical School New Brunswick, NJ

Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.

Can Sequentially Reactive EIA’s Replace HIV-1 Western Blot Testing? Robert A. Myers Ph.D.

HIV Diagnostics and A New Testing Algorithm

12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.

An Introduction to HIV Incidence Surveillance (HIS) in California California Department of Public Health Office of AIDS.

APHL CLIA Training Projects Karen Breckenridge, MBA, MT(ASCP) CLIAC Meeting March 5, 2014.

Implementing RTA to Identify False Positives and Immediately Refer to Care Thomas Knoble, Omar Menendez, Teri Dowling, Shelley Facente San Francisco Department.

CDC HIV Diagnostics Conference December 5-7, 2007 Sensitivity of OraQuick and Early Generation Enzyme Immunoassay (EIA) within a Pooled HIV Nucleic Acid.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.

Implementation of Rapid Testing from a Rural Perspective - Keys to Success Susanne Norris Zanto, CLS(NCA) Montana Public Health Laboratory

Increasing Our Reach through Rapid HIV Testing Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and.

Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,

Can a second rapid HIV test discriminate false positives as effectively as a Western Blot? The NJ Experience Evan M. Cadoff, MD Robert Wood Johnson Medical.

METHODS  Based on initial OraQuick Post-Marketing Survey, the CDC made the recommendation that a discordant result should be followed-up by antibody testing.

California Department of Public Health Office of AIDS Guide for Health Department Surveillance Staff Collecting Data on the new Testing and Treatment History.

Evaluation of Commercially Available HIV Assays to Address Alternative Screening/Diagnostic Algorithms S. Michele Owen, Ph.D. Laboratory Branch Division.

THE EFFECTIVENESS OF A RE- TESTING PROTOCOL TO ASSURE QUALITY DNA PCR TESTING FOR EARLY INFANT DIAGNOSIS (EID) IN MALAWI XVIII INTERNATIONAL AIDS CONFERENCE.

HIV Testing CDC power point edited by M. Myers

HIV Diagnosis: New Tests, New Algorithms and a New Focus Berry Bennett, MPH Retrovirology Section Chief FL Bureau of Public Health Laboratories, FDOH

APHL Survey HIV Diagnostic Testing Utilization Barbara G. Werner, PhD MA State Laboratory Institute February 28, 2005.

Shelley Facente, Thomas Knoble, Omar Menendez, Teri Dowling San Francisco Department of Public Health, HIV Prevention Section Kevin Delaney Division of.

Implementing Rapid HIV Testing in New York State Mara San Antonio-Gaddy Director Bureau of Direct Program Operations NYSDOH, AIDS Institute.

HIV Rapid Testing Dr. Kevin Harvey National HIV/AIDS Programme Ministry of Health Jamaica.

Incorporation of the Aptima® HIV-1 RNA Assay into Serodiagnostic and Rapid Test Confirmation Testing Algorithms to Resolve Discordant Serological Results.

HIV Testing Quality Assurance and Quality Control

Results from the LA rapid testing study: What can they tell us about proposed point of care strategies? Kevin Delaney, MPH Division of HIV/AIDS Prevention.

Roll-out and Implementation of Rapid Testing from a Field Perspective Perspectives from San Francisco Shelley Facente, MPH Rapid HIV Testing Program Coordinator.

Rapid HIV Testing: 2003 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and Prevention.

Evaluation of a Proposed Testing Strategy for Laboratory-based Testing Using an HIV-1/2 Discriminatory Assay for HIV: Strategy 5 Data Needs. R. Boromisa,

Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.

Performance of rapid HIV tests used singly and in combination: Moving toward a point of care diagnosis. Kevin Delaney, MPH HIV Diagnostics: New Developments.

Figure 1 A Case Series of Discordant Laboratory Results with Statewide Rapid HIV Testing in New Jersey Eugene G Martin, PhD 1, Gratian Salaru, MD 1, Sindy.

Limitations of HIV Antibody Testing in a Population with High Incidence of HIV Infection Joanne Stekler 1,2, Paul D. Swenson 1,2, Robert W. Coombs 1, Joan.

RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.

Development of a detuned oral assay for recent HIV infection F. Priddy 1, P. Phelan 1, P. Tambe 1,2, C. del Rio 1 1 Emory University School of Medicine,

Reducing the Delay: Can a Rapid HIV Test Discriminate False Positives as Effectively as a Western Blot – the NJ Experience Eugene G. Martin, Ph.D. *, Gratian.

ORAQUICK RAPID HIV TEST Medical Center of Louisiana Cynthia Eicher, MHS MT(ASCP)SBB Denise Friloux, RN, BSN, CIC.

Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.

HIV diagnosis (general) ImmunoassaysNAT (PCR)

In the Footsteps of the WHO – Rapid HIV Testing in America Eugene Martin, Ph.D. *, Gratian Salaru, M.D. *, Sindy M. Paul, M.D., M.P.H.**, Evan Cadoff,

E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.

1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.

Further information: Performance of HIV Enzyme-Immunoassays on Dried Blood Spots for Quality Control of HIV Testing Dennis Olara 1,

Introduction to OraQuick Rapid HIV Testing William F. Ryan Community Health Center School Based Health Program.

Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,

If the serum specimen fails to confirm, the frozen white top tube is collected by staff from NJ HIV and sent frozen overnight to ARUP laboratories (Salt.

CATHERINA JEMMOTT NOVEMBER 26TH, health districts 7 district health teams 52 health centre/clinics 2 district hospitals Main hospital in Roseau.

RETROVIRIDAE GENUS: ONCOVIRUS: HTLV-1 and HTLV-2 SPUMAVIRUS LENTIVIRUS: HIV-1 and HIV-2.

Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors Michael P. Busch representing Blood Systems Research Institute Blood.

California Clinical Laboratory Association

In the Footsteps of the WHO – Rapid HIV Testing in America

INTEGRATING HIV AND HCV TESTING.

AIDS in the United States

A CASE SERIES OF DISCORDANT LABORATORY RESULTS WITH RAPID HIV TESTING

Challenges for Blood Donor Confirmatory Testing Algorithms

Presentation transcript:

Resolution of Discordant Confirmatory Results on POC Reactive Rapid Tests: Florida’s Pilot Project HIV Diagnostics: New Developments and Challenges Feb. 28, 2005 Berry Bennett, MPH Retrovirology Section Chief FL. Bureau of Laboratories Jacksonville, FL.

Public Health Laboratories (PHL) Role in Rapid HIV Testing Provide Confirmation testing on POC presumptive positive rapid tests. Provide quality assurance testing on POC negatives, if applicable? Participate in site specific QA programs - provide technical training needs - provide blood borne pathogen and biohazard safety training - provide proficiency samples and/or encourage CDC’s MPEP enrollment. - provide competency evaluations (site visits?) - provide verification samples and/or quality controls more?? (regulatory consults, troubleshooting, etc.) In July/August 2004 the Association of Public Health Laboratories (APHL) conducted a survey of 56 state and territorial PHLs to assess HIV diagnostic testing practices. The survey included questions as to utilization of rapid tests within PHLs and the roles that PHLs have played in training for non-traditional testing facilities. - Approximately 10% of the respondents indicated use of rapid tests (in-house algorithm vs. study related vs. off-site PHL supported, not specified). - 45% of PHLs have delivered at least one rapid HIV training course, either their own design or CDC.

Confirmation Algorithm* for HIV Rapid Testing POC presumptive positive rapid test HIV-1 Western blot or IFA (serum, plasma, dbs)(Orasure W.Blot only) PositiveNegativeIndeterminate Report as Report asReport as HIV-1 PositiveHIV-1 Negative,HIV-1 Indeterminate, request blood(blood) advise 30 day retest.follow up, (Orasure) request blood retest. * CDC Guidelines for a Quality Assurance Program,March, 31,

Florida Confirmation Algorithm for HIV Rapid Testing POC presumptive positive rapid test HIV-1 Western blot HIV-1/2 Plus O EIA (serum, plasma, dbs, Orasure) HIV-1 Orasure EIA (comparative purposes) PositiveNegativeIndeterminate Report asHIV-2 testing (serum, plasma) HIV-1 PositiveOraQuick retesting (serum, plasma) Unigold HIV-1 (comparative purposes) possible STARHS case (serum, plasma) (except Orasure)

Expectations in the Confirmation of POC Presumptive Positive Rapid Tests? Provide quick TAT (county jails, drug treatment centers, ERs) Adjust traditional testing algorithms to accommodate a quick TAT Serum, plasma or dbs are preferred specimens however Orasure may be the only alternative for some sites. Provide additional testing (NAAT, Ag+, etc) or refer to CDC to resolve discordance between rapid and traditional laboratory results.

Florida Department of Health OraQuick Pilot Study (Summer 2003 – Dec. 2004) POC tests performed = 27,473 POC negative results = 26,695 POC “presumptive positives” = 778 Lab-confirmed positives = 764 (98%) Initial rapid tests non-confirmed ‡ = 14* Seropositivity rate = 2.78% ‡ Western Blot negative or indeterminate. * (7) confirmation specimen submitted was unsatisfactory for rapid retesting. (4) OraQuick negative upon repeat (possible POC user misinterpreted) (3) OraQuick positive upon repeat (assay false positive)

Discordant Review of POC Presumptive Positive OraQuicks: Florida, Summer 2003 – 12/31/2004 Confirmation traditional lab-basedlab-based other sampleresultsrapid retesting oral fluid (7)HIV-1 EIA r/r (3/7) N/A Unconfirmed reports of HIV-1 W Blot Ind. (3) seroconversion outside PH testing HIV-1 EIA nr (4/7) N/A N/A HIV-1 W Blot neg. (2) HIV-1 W Blot Ind. (1) serum (7)HIV-1/2 EIA nr (7/7)OraQuick pos. (3/7) <75 RNA copies/ml (1) HIV-1 W Blot neg. (7/7)* Unigold neg. (3) HIV-2 EIA nr (7/7) OraQuick neg. (4/7) Unigold neg. (3) Unigold n/a (1) All cases are being monitored for seroconversion, poor client return rates thus far. * One individual w/ initial W Blot Ind., negative on redraw

BBI Seroconversion Panel Results: G.S. G.S days since HIV-1/2 HIV-1/2 Unigold OraQuick Member#1 st bleedSP Plus O HIV-1r (20) (40) PRB N NN PRB N NN PRB N NN PRB N NN PRB N NN PRB wP NN BBI BOLBOL BOL C.B. W Blot RT-PCR PRB958-01no bands 2 X no bands2 X no bands 2 X no bands 5 X no bands 4 X no bands >8 X 10 5 BBIBBI

BBI Seroconversion Panel Results: G.S. G.S days since HIV-1/2 HIV-1/2 Unigold OraQuick Member#1 st bleedSP Plus O HIV-1r (20) (40) PRB N NN PRB N NN PRB N NN PRB P PP PRB P PP PRB P PP PRB P PP BBI BOL BOL BOL C.B. W Blot RT-PCR PRB959-01no bands 2 X no bands >8 X no bands >8 X p24, gp160 8 X p24, gp160 5 X p24, gp160 3 X p24, gp160 >8 X 10 5 BBIBBI

Florida Lessons Learned (thus far) : Altering our algorithm has improved rapid confirmation TAT. Is it advisable as numbers increase and testing sites vary? Follow up success on discordant cases is dependant on POC testing site. Ex. Jail settings are better than some PH clinics. Repeating rapid tests in the laboratory, if possible, on POC presumptive positive cases is a valuable tool in differentiating user vs. assay discordance. Sample choice in the confirmation process may limit additional testing needs. We clearly have discordance between rapid assays. Need for further investigations! We recommend enlisting CDC’s assistance early in the process.